Traditional de novo drug discovery, which typically presents an 11% approval rate from
phase I trials and even higher failure rates in fields like neurodegeneration, often requires …

Drug repurposing can be cheaper and faster than developing new compounds. Yet, it
remains underused, partially because of regulatory and intellectual property challenges …

Drug innovation traditionally follows a de novo approach with new molecules through a
complex preclinical and clinical pathway. In addition to this strategy, drug repositioning has …

Mapping the patent landscape of medical machine learning | Nature Biotechnology Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

The sufficiency of disclosure of medical artificial intelligence patents | Nature Biotechnology
Skip to main content Thank you for visiting nature.com. You are using a browser version with …

The escalating costs and high failure rates have decelerated the pace of drug development,
which amplifies the research interests in developing combinatorial/repurposed drugs and …

Commentators claim that drug repositioning (ie developing new uses for authorised drugs)
significantly slows when generics are authorised and, therefore, law reform is necessary to …

This chapter examines the regulatory landscape of drug regulation in the European Union. It
provides an overview of the key institutions and mechanisms responsible for ensuring the …

Background: Drug repurposing (DR) refers to the practice of identifying new uses for existing
drugs. This practice has the potential to provide a faster and less costly alternative to …

The issues around financial and regulatory obstacles to the repurposing of off-patent/generic
medicines are well characterised in the academic literature and are familiar to policymakers …